| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2022 | CUREBIOTECH, INC. | 358 DEHNHOFF WALK | OCEAN BEACH | NY | 11770 | SUFFOLK | USA | R41CA268252 | Combination of CB101 and radiation therapy in head and neck squamous cell carcinoma | 000 | 1 | NIH | 8/9/2024 | $0 |
| | 2024 | 2020 | CUREBIOTECH, INC. | 358 DEHNHOFF WALK | OCEAN BEACH | NY | 11770 | SUFFOLK | USA | R44CA217489 | Intratumoral immunotherapy with formulated resiquimod for metastatic melanoma | 000 | 4 | NIH | 12/14/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2022 | CUREBIOTECH, INC. | 3401 GRAYS FERRY AVE STE 209 | PHILADELPHIA | PA | 19146-2701 | PHILADELPHIA | USA | R41CA268252 | Combination of CB101 and radiation therapy in head and neck squamous cell carcinoma | 000 | 1 | NIH | 12/1/2022 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $250,876 ) |
| | 2022 | 2022 | CUREBIOTECH, INC. | 3401 GRAYS FERRY AVE STE 209 | PHILADELPHIA | PA | 19146-2701 | PHILADELPHIA | USA | R41CA268252 | Combination of CB101 and radiation therapy in head and neck squamous cell carcinoma | 000 | 1 | NIH | 8/30/2022 | $250,876 |
| | 2022 | 2020 | CUREBIOTECH, INC. | 3401 GRAYS FERRY AVE STE 209 | PHILADELPHIA | PA | 19146-2701 | PHILADELPHIA | USA | R44CA217489 | Intratumoral immunotherapy with formulated resiquimod for metastatic melanoma | 000 | 4 | NIH | 3/11/2022 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $974,959 ) |
| | 2020 | 2020 | CUREBIOTECH, INC. | 3401 GRAYS FERRY AVE STE 209 | PHILADELPHIA | PA | 19146-2701 | PHILADELPHIA | USA | R44CA217489 | Intratumoral immunotherapy with formulated resiquimod for metastatic melanoma | 000 | 4 | NIH | 3/3/2020 | $974,959 |
|
| Issue Date FY: 2019 ( Subtotal = $1,024,973 ) |
| | 2019 | 2019 | CUREBIOTECH, INC. | 3624 MARKET ST | PHILADELPHIA | PA | 19104-2614 | PHILADELPHIA | USA | R44CA217489 | Intratumoral immunotherapy with formulated resiquimod for metastatic melanoma | 000 | 3 | NIH | 3/6/2019 | $1,024,973 |
| | 2019 | 2017 | CUREBIOTECH, INC. | 3401 GRAYS FERRY AVE STE 209 | PHILADELPHIA | PA | 19146-2701 | PHILADELPHIA | USA | R43CA217489 | Novel injectable resiquimod formulation for treatment of metastatic cancers | 000 | 2 | NIH | 11/20/2018 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $0 ) |
| | 2018 | 2017 | CUREBIOTECH, INC. | 8 HEATHCOTE DR | ALBERTSON | NY | 11507-2210 | NASSAU | USA | R43CA217489 | Novel injectable resiquimod formulation for treatment of metastatic cancers | 000 | 2 | NIH | 6/21/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $202,854 ) |
| | 2017 | 2017 | CUREBIOTECH, INC. | 8 HEATHCOTE DR | ALBERTSON | NY | 11507-2210 | NASSAU | USA | R43CA217489 | Novel injectable resiquimod formulation for treatment of metastatic cancers | 002 | 2 | NIH | 5/12/2017 | $202,854 |
|
|
